Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD/FSGS and in patients who have experienced relapse of FSGS post-transplant, compared to those of a control group of patients with nephrotic syndrome due to primary membranous nephropathy (MN).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult (\>18 years) males and females
• Patients with biopsy-proven idiopathic MCD or FSGS (cases)
• Patients with biopsy-proven idiopathic membranous nephropathy (controls)
• Patients who provided consent to store their samples in the certified CRB biobank
Locations
Other Locations
Italy
Clinical Research Center for Rare Disease Aldo e Cele Daccò
RECRUITING
Ranica
Contact Information
Primary
Federica Casiraghi, PhD
federica.casiraghi@marionegri.it
+3903545351
Backup
Norberto Perico, MD
norberto.perico@marionegri.it
+3903545351
Time Frame
Start Date: 2024-03-19
Estimated Completion Date: 2028-03
Participants
Target number of participants: 100
Treatments
Cases
Sera from patients with biopsy-proven idiopathic MCD or FSGS who provided consent to store their samples in the certified biobank (Mario Negri Biological Resources Centre - Rare Diseases and Renal Diseases Biobank - CRB). Serum samples will be tested for the levels of anti-nephrin autoantibodies by in-house ELISA and results confirmed by commercial ELISA kits.
Controls
Sera from patients with biopsy-proven idiopathic membranous nephropathy who provided consent to store their samples in the certified biobank (Mario Negri Biological Resources Centre - Rare Diseases and Renal Diseases Biobank - CRB). Samples will be tested for the levels of anti-nephrin autoantibodies by in-house ELISA and results confirmed by commercial ELISA kits.
Related Therapeutic Areas
Sponsors
Leads: Mario Negri Institute for Pharmacological Research